Wigobi Pushes for Health Insurance Coverage… Price Competition for Obesity Drugs Intensifies
4 Articles
4 Articles
Health insurance coverage for the obesity treatment drug 'Wigobi' is being pursued. If Wigobi is covered by health insurance, the costs borne by patients could be reduced. According to the pharmaceutical industry on the 12th, Novo Nordisk Korea recently submitted an application for a decision on health insurance medical benefits for Wigobi to the Health Insurance Review and Assessment Service (HIRA). A Novo Nordisk Korea official stated, "Obesit…
(Seoul = Yonhap News) Reporter Park Sang-hyun = Novo Nordisk is pushing for health insurance coverage for its glucagon-like peptide-1 (GLP-1) class obesity treatment drug 'Wigobi'.
Novo Nordisk Korea has submitted an application for a decision on health insurance reimbursement for its obesity treatment drug, Wigobi, to the Health Insurance Review and Assessment Service (HIRA). This marks the first application for reimbursement listing for a GLP-1 (glucagon-like peptide-1) class obesity treatment. The target recipients for this reimbursement application include patients with severe obesity, overweight or obese patients acc…
Novo Nordisk has begun the process of adding its obesity treatment drug, Wigobi, to the national health insurance coverage list.
Coverage Details
Bias Distribution
- 100% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
